株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

低血圧症:パイプライン製品の分析

Hypotension - Pipeline Review, H1 2019

発行 Global Markets Direct 商品コード 465224
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.75円で換算しております。
Back to Top
低血圧症:パイプライン製品の分析 Hypotension - Pipeline Review, H1 2019
出版日: 2019年01月31日 ページ情報: 英文 50 Pages
概要

低血圧症は、心拍数が通常よりかなり低い時や、その後に起こります。その時、心臓、脳をはじめ、体内のその他の部分に十分な血液が流れていません。症状は、視力障害や、目まい、混乱、不眠や虚弱などです。症候のある患者には治療が必要です。

当レポートでは、低血圧症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

低血圧症;概要

治療薬の開発

  • パイプライン製品;概要
  • 企業別のパイプライン製品
  • 企業で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Anexon Inc
  • BCO Pharma Ltd
  • La Jolla Pharmaceutical Company
  • Theravance Biopharma Inc
  • TrioxBio Inc

薬剤プロファイル

  • angiotensin II acetate
  • ANX-042
  • dopamine hydrochloride
  • MTR-105
  • MTR-107
  • TD-9855

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Hypotension, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Hypotension - Pipeline by Cerecor Inc, H1 2019
  • Hypotension - Pipeline by Handa Pharmaceuticals LLC, H1 2019
  • Hypotension - Pipeline by La Jolla Pharmaceutical Company, H1 2019
  • Hypotension - Pipeline by Theravance Biopharma Inc, H1 2019
  • Hypotension - Pipeline by TrioxBio Inc, H1 2019
  • Hypotension - Dormant Projects, H1 2019

List of Figures

  • Number of Products under Development for Hypotension, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Targets, H1 2019
  • Number of Products by Stage and Targets, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
目次
Product Code: GMDHC11029IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension - Pipeline Review, H1 2019, provides an overview of the Hypotension (Cardiovascular) pipeline landscape.

Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Treatment is required for patients with signs and symptoms.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypotension - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hypotension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypotension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypotension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Unknown stages are 1, 2, 1, 2 and 1 respectively.

Hypotension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypotension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Hypotension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypotension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypotension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypotension (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypotension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypotension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypotension - Overview
  • Hypotension - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Hypotension - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hypotension - Companies Involved in Therapeutics Development
    • Cerecor Inc
    • Handa Pharmaceuticals LLC
    • La Jolla Pharmaceutical Company
    • Theravance Biopharma Inc
    • TrioxBio Inc
  • Hypotension - Drug Profiles
    • ampreloxetine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • angiotensin II acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dopamine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HND-024 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTR-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTR-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rislenemdaz - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hypotension - Dormant Projects
  • Hypotension - Product Development Milestones
    • Featured News & Press Releases
      • Jan 29, 2019: Theravance doses first patient in Phase II trial of ampreloxetine
      • Aug 01, 2018: Theravance Biopharma reports positive top-line four-week data from phase 2 trial of TD-9855 for the treatment of symptomatic neurogenic orthostatic hypotension
      • May 29, 2018: TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten for the Treatment of Intradialytic Hypotension
      • Sep 25, 2017: La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018
      • Sep 20, 2017: Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State
      • Aug 28, 2017: La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501
      • Aug 08, 2017: La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501
      • May 21, 2017: Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine
      • Feb 27, 2017: La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501
      • Nov 30, 2015: La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501
      • Feb 09, 2015: La Jolla Pharmaceutical Company Announces Special Protocol Assessment for Planned Phase 3 Trial of LJPC-501 in Catecholamine-Resistant Hypotension
      • Jul 08, 2014: La Jolla Pharmaceutical Company Announces Planned Initiation of Phase 3 Registration Program for LJPC-501 in Resistant Hypotension
      • Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II Trial Of Droxidopa In Intradialytic Hypotension
      • Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II Trial Of Droxidopa In Intradialytic Hypotension
      • Nov 03, 2008: Chelsea Therapeutics Reports Significant Reduction In Severity Of Symptoms During Titration Phase Of Pivotal Droxidopa Study In Neurogenic Orthostatic Hypotension
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top